Actively Recruiting
Phase 1 Study of Oral ONO-6414 to Evaluate Safety, Tolerability, and Pharmacokinetics in Healthy Adults and Patients With Active Ulcerative Colitis
Led by Ono Pharmaceutical Co., Ltd. · Updated on 2026-09-09
90
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacokinetics of an oral drug called ONO-6414 in healthy adults and patients with active ulcerative colitis UC. This phase 1, randomized, double-blind, placebo-controlled trial aims to understand how ONO-6414 behaves in the body and its immediate safety profile. The study includes healthy volunteers and UC patients to explore different dosing and food effects. Participants receive ONO-6414 orally in different ways depending on their group a single ascending dose, multiple ascending doses for seven consecutive days, or a single open-label dose for UC patients. Some participants may also receive placebo as part of the randomized design. The study measures drug levels in the blood and evaluates the effect of food on the drugs absorption. During the study, participants undergo medical evaluations including vital signs, ECGs, and laboratory tests. Researchers monitor adverse events up to 168 hours after dosing and collect blood samples up to 72 hours post-dose to measure pharmacokinetic parameters like peak concentration and total exposure. Participants must abstain from certain substances and follow study procedures, with a total participation period that includes dosing and follow-up assessments.
CONDITIONS
Brief Title
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis
Research Team
N
North America Clinical Trial Support Desk
I
International Clinical Trial Support Desk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here